CYCLOPENTOLATE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CYCLOPENTOLATE HYDROCHLORIDE (CYCLOPENTOLATE HYDROCHLORIDE).
Antimuscarinic agent; blocks acetylcholine at muscarinic receptors in the sphincter and ciliary muscles of the iris, producing mydriasis and cycloplegia.
| Metabolism | Primarily hepatic metabolism via ester hydrolysis in plasma and liver; limited data on specific CYP enzymes. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; the remainder is biliary/fecal. |
| Half-life | Terminal elimination half-life is approximately 2.5 hours in adults; shorter in children (~1-2 hours) and prolonged in elderly or hepatic impairment. |
| Protein binding | Approximately 60-70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Ophthalmic: systemic bioavailability is low (approx. 1-5%) due to limited corneal absorption and nasolacrimal drainage; oral bioavailability is not clinically relevant. |
| Onset of Action | Ophthalmic: mydriasis within 5-15 minutes; cycloplegia within 15-30 minutes. |
| Duration of Action | Mydriasis lasts up to 24 hours; cycloplegia may persist for 6-24 hours depending on dose and individual response. |
| Molecular Weight | 327.89 |
1-2 drops of 0.5-1% solution, repeat in 5-10 minutes if necessary; or 0.1-0.5 mL of 1% solution subconjunctivally.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required; drug is primarily metabolized locally and systemically with minimal renal excretion. |
| Liver impairment | No dose adjustment required; drug is metabolized locally and systemically, but hepatic impairment unlikely to affect ocular efficacy. |
| Pediatric use | Infants and children: 1 drop of 0.5-1% solution, may repeat once after 5 minutes; maximum 2 drops per eye. |
| Geriatric use | Use lower concentration (0.5%) due to increased risk of systemic side effects and prolonged cycloplegia; monitor for acute angle-closure glaucoma. |
| 1st trimester | Limited human data; no known teratogenicity in animal studies. Use only if clearly needed. |
| 2nd trimester | Limited human data; no known fetal harm. Use only if clearly needed. |
| 3rd trimester | Limited human data; no known fetal harm. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for CYCLOPENTOLATE HYDROCHLORIDE (CYCLOPENTOLATE HYDROCHLORIDE).
| Placental transfer | Limited data; likely crosses placenta due to low molecular weight (327.89 Da). |
| Breastfeeding | Systemic absorption is minimal after ophthalmic use, but infants with G6PD deficiency may be at risk for hemolytic anemia. Monitor infant for anticholinergic effects (dry mouth, dilated pupils, tachycardia). |
| Lactation Rating |
■ FDA Black Box Warning
No FDA boxed warning exists.
| Serious Effects |
Hypersensitivity to cyclopentolate or any component of the formulationNarrow-angle glaucomaUntreated angle-closure glaucoma
| Precautions | May increase intraocular pressure; use with caution in glaucoma or narrow iridocorneal angle, Central nervous system effects (e.g., hallucinations, confusion, behavioral disturbances) especially in children, Photophobia and blurred vision due to mydriasis, Tachycardia and hypertension with systemic absorption |
| Food/Dietary | No specific food interactions. Maintain adequate hydration to minimize dry mouth. Avoid alcohol and sedatives as they may potentiate drowsiness and blurred vision. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: No human data; animal studies not conducted; theoretical risk of systemic anticholinergic effects at high doses. Second/third trimester: Limited reports; no evidence of teratogenicity with ophthalmic use; potential for fetal tachycardia if systemic absorption occurs. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure for systemic anticholinergic effects; fetal heart rate monitoring if maternal tachycardia occurs. |
| Fertility Effects | No known effects on fertility; no human or animal data available. |
| Clinical Pearls |
| Cyclopentolate is an anticholinergic agent used for mydriasis and cycloplegia. Onset of action is 15-30 minutes with duration up to 24 hours. Use the lowest effective concentration (0.5% in infants, 1% in children, 2% in adults) to minimize systemic effects. Monitor for central nervous system toxicity, especially in children and elderly. Reversal with pilocarpine is possible but not recommended. Avoid in patients with narrow-angle glaucoma or known hypersensitivity. |
| Patient Advice | Temporary blurred vision and sensitivity to light are expected after use. Wear sunglasses indoors and avoid driving or hazardous activities until vision clears. · Do not touch the dropper tip to any surface to avoid contamination. Wait at least 5 minutes between different eye drops. · Notify your doctor if you experience eye pain, severe headache, rapid heartbeat, confusion, or difficulty urinating. · For children: monitor for flushing, fever, dry mouth, or unusual behavior which may indicate systemic absorption. · Wash hands before and after administration. Apply pressure to the tear duct (inner corner of eye) for 1-2 minutes after instillation to reduce systemic absorption. |